Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases
PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or os...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1997-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1080/09629359791758 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556074813620224 |
|---|---|
| author | P. Vergne V. Praloran R. Treves Y. Denizot |
| author_facet | P. Vergne V. Praloran R. Treves Y. Denizot |
| author_sort | P. Vergne |
| collection | DOAJ |
| description | PAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial fluid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases. |
| format | Article |
| id | doaj-art-8a690fb1f643444eab1cf0f27df1b886 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1997-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-8a690fb1f643444eab1cf0f27df1b8862025-02-03T05:46:26ZengWileyMediators of Inflammation0962-93511466-18611997-01-016324124210.1080/09629359791758Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseasesP. Vergne0V. Praloran1R. Treves2Y. Denizot3Service de Rhumatologie, CHRU Dupuytren, 2 rue M. Luther King, Limoges 87042, FranceLaboratoire d'Hématologie Expérimentale, Faculté de Médecine, 2 rue Dr. Marcland, Limoges 87025, FranceService de Rhumatologie, CHRU Dupuytren, 2 rue M. Luther King, Limoges 87042, FranceLaboratoire d'Hématologie Expérimentale, Faculté de Médecine, 2 rue Dr. Marcland, Limoges 87025, FrancePAF is a potent inflammatory compound known to stimulate the release of various cytokines involved in rheumatic diseases. Elevated blood PAF levels are reported in these patients. We report that serum PAF acetylhydrolase activity (AHA) levels are decreased in patients with rheumatoid arthritis or osteoarthritis as compared to healthy controls. Serum and synovial fluid AHA levels were correlated in these patients. The present study suggests the potential role of AHA in controling systemic and/or local PAF levels in patients with rheumatic diseases.http://dx.doi.org/10.1080/09629359791758 |
| spellingShingle | P. Vergne V. Praloran R. Treves Y. Denizot Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases Mediators of Inflammation |
| title | Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases |
| title_full | Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases |
| title_fullStr | Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases |
| title_full_unstemmed | Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases |
| title_short | Decreased levels of serum platelet-activating factor acetylhydrolase in patients with rheumatic diseases |
| title_sort | decreased levels of serum platelet activating factor acetylhydrolase in patients with rheumatic diseases |
| url | http://dx.doi.org/10.1080/09629359791758 |
| work_keys_str_mv | AT pvergne decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases AT vpraloran decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases AT rtreves decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases AT ydenizot decreasedlevelsofserumplateletactivatingfactoracetylhydrolaseinpatientswithrheumaticdiseases |